Emodin reverses leukemia multidrug resistance by competitive inhibition and downregulation of P-glycoprotein

Hongping Min¹,², Miaomiao Niu¹,², Weilin Zhang¹,², Jia Yan¹,², Jiachang Li³, Xiying Tan⁴, Bo Li¹,², Mengxiang Su¹,², Bin Di¹,²*, Fang Yan¹,²*

¹ Key Laboratory on Protein Chemistry and Structural Biology, China Pharmaceutical University, Nanjing, China, 2 Key Laboratory of Drug Quality Control and Pharmacovigilance (China Pharmaceutical University), Ministry of Education, Nanjing, China, 3 Department of Pharmacology, China Pharmaceutical University, Nanjing, China, 4 Jiangsu Province Hospital of Chinese Traditional Medicine, Nanjing, China

* dibin@cpu.edu.cn (BD); cpuyanfang@hotmail.com (FY)

Abstract

Development of multidrug resistance (MDR) is a continuous clinical challenge partially due to the overexpression of P-glycoprotein (P-gp) for chronic myelogenous leukemia (CML) patients. Herein, we evaluated the inhibitory potency of emodin, a natural anthraquinone derivative isolated from *Rheum palmatum* L, on P-gp in P-gp positive K562/ADM cells. Competition experiments combined with molecular docking analysis were utilized to investigate the binding modes between emodin and binding sites of P-gp. Emodin reversed adriamycin resistance in K562/ADM cells accompanied with the decrease of P-gp protein expression, further increasing the uptake of rhodamine123 in both K562/ADM and Caco-2 cells, indicating the inhibition of P-gp efflux function. Moreover, when incubated with emodin under different conditions where P-gp was inhibited, K562/ADM cells displayed increasing intracellular uptake of emodin, suggesting that emodin may be the potential substrate of P-gp. Importantly, rhodamine 123 could increase the \( K_{\text{intrinsic}} \) value of emodin linearly, whereas, verapamil could not, implying that emodin competitively bound to the R site of P-gp and non-competition existed between emodin and verapamil at the M site, in a good accordance with the results of molecular docking that emodin bound to the R site of P-gp with higher affinity. Based on our results, we suggest that emodin might be used to modulate P-gp function and expression.

Introduction

Chronic myelogenous leukemia (CML) results from the neoplastic transformation of hematopoietic stem cell. The hallmark genetic abnormality of CML is a t(9;22)(q34;q11) translocation named the "Philadelphia chromosome", which generates the BCR–ABL fusion gene [1, 2]. In the past decades, development of specific TKIs such as imatinib (IM) revolutionized the treatment of CML, however, a significant number of patients develop drug resistance, especially in late stages of the disease. The drug resistance mechanisms involve many
factors, which are mainly divided into Bcr/abl-dependent and Bcr/abl-independent mechanisms [3]. Among the latter is the MDR phenotype which is mostly associated with the over-expression of P-glycoprotein (P-gp) [4]. P-gp, an ATP-binding cassette (ABC) membrane transporter encoded by multidrug resistance 1 (MDR1), is commonly located at the plasma membrane and has been demonstrated to function as an ATP-dependent efflux pump for diverse naturally occurring hydrophobic anticancer drugs such as adriamycin [5]. As a consequence of this, many anticancer regents could not accumulate in tumor cells efficiently to reach the sufficient therapeutic concentrations and led to MDR [6]. Therefore, it is necessary to develop P-gp inhibitors to modulate its pumping activity so as to circumvent P-gp mediated MDR in CML.

Emodin (1, 3, 8-trihydroxy-6-methylanthraquinone) (Fig 1), a natural anthraquinone derivative isolated from Rheum palmatum L., has been reported to potentiate the anti-proliferation of various chemotherapeutic agents [7]. It is demonstrated that emodin reverses MDR in resistant HL-60/ADR cells [8], and emodin and AZT exhibit synergistic growth-inhibitory effects in K562/ADM cells [9]. In addition, emodin is confirmed to be the inhibitor of P-gp by inhibiting P-gp efflux function and protein expression in Caco-2 cells [10]. Subsequently, it is proposed that emodin is the potential substrate of P-gp and further hypothesized that emodin inhibits the P-gp function by competitively binding to the transport sites [11]. However, it is unreported whether emodin could reverse the adriamycin resistance in K562/ADM cells. Moreover, whether emodin is the inhibitor and substrate of P-gp is controversial in different experimental conditions [11, 12]. Importantly, it has to be noted that the hypothesis about the binding modes of emodin on P-gp by Li et al is only based on the molecular docking analysis without accurate experimental data, and to date, the definite binding sites of emodin on P-gp are not clear yet. Hence, more direct experimental data and more detailed molecular docking analysis are urgently needed to illuminate the binding sites of emodin on P-gp.

In this paper, we investigated the reversal effects of emodin in adriamycin resistant K562/ADM cells and its inhibitory effects on P-gp protein expression as well as its efflux function. Serial studies were performed aiming to clarify whether emodin is the substrate of P-gp and the competition experiments combined with molecular docking analysis were also designed to clarify the binding sites of emodin on P-gp. 

![Chemical structure of emodin](https://doi.org/10.1371/journal.pone.0187971.g001)
Materials and methods

Chemicals and drugs
Verapamil, Adriamycin, cyclosporine A, rhodamine 6G, chrysophanol and rhodamine123 were purchased from Biosharp (Nanjing, China). Emodin and 3-[4, 5-dimethyl thiazol-2-y]-2, 5-diphenyl terazolium bromide (MTT) were bought from Sigma-Aldrich (St. Louis, USA). The BCA Protein Assay kit and RIPA lysis buffer were obtained from Beyotime (Beijing, China). Enhanced chemiluminescence (ECL) detection kit was from Advansta (Menlo Park, California, USA). The Annexin V Apoptosis Detection Kit APC and DAPI were available from eBioscience (San Diego, CA). The Lipofectamine RNAiMAX Reagent was purchased from Invitrogen Trading Co., Ltd (Shanghai, China).

Cell lines and cell culture
Human myelogenous myeloid leukemia (K562) cells and the P-gp overexpressing Adriamycin-resistant K562 cells (K562/ADM) were obtained from Institute of Hematology of Chinese Academy of Medical Sciences (Tianjin, China). All CML cell lines were cultured in RPMI 1640 media (Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10% fetal bovine serum (FBS) (Gibco BRL, Grand Island, NY, USA), 100 U/ml of penicillin and 100 μg/ml of streptomycin (Sigma, St. Louis, Mo, USA) at 37˚C in a humidified atmosphere of 5% CO₂. K562/ADM cells were cultured in the presence of 5 μg/ml Adriamycin. Before the experiments, adriamycin was withdrawn from the cells for two weeks.

The Caco-2 cell line (ATCC #HTB-37) was purchased from the American Type Culture Collection. The Caco-2 cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) (Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10% FBS, 100 U/ml of penicillin and 100 μg/ml of streptomycin at 37˚C in a humidified atmosphere of 5% CO₂.

Cell cytotoxicity assay
To determine the dose-dependent and time-dependent cytotoxicity of emodin, 6×10⁴ cells/well of K562 and K562/ADM (cells grown in suspension) were seeded in 96-well plates. The cytotoxicity was assessed using the conventional MTT assay as reported with minor modification [13]. The emodin incubation time is 24, 48 or 72 h. Cell viability was calculated according to the formula: viability% = (OD emodin treated cells − OD emodin medium control)/(OD untreated cells − OD medium control)× 100%

For Caco-2 (cells grown in adherence), 2×10⁴ cells/well were seeded in 96-well plates and incubated for 24 h, then the MTT assay was carried out as described above.

Assay of the reversal efficacy
The potential of emodin to reverse MDR was evaluated by the MTT method in the K562/ADM cell line. K562/ADM cells were seeded into 96-well plates (6×10⁴ cells each well). Subsequently, Adriamycin only or combinations with emodin (1–40 μM) or Verapamil (10μM) diluted in RPMI1640 were added. The cells were maintained at 37˚C in a humidified atmosphere of 5% CO₂ for 48 h, and the percentages of viable cells were evaluated by the MTT assay and plotted against concentrations of the emodin to determine their half maximal inhibitory concentration (IC₅₀). The reversal fold (RF) values were calculated according to the following formula: RF = IC₅₀ of adriamycin alone/ IC₅₀ of adriamycin combined with emodin. Each assay was repeated thrice.
Apoptosis assay
K562/ADM cells (1×10^6 cells/ml) were seeded in 6-well plates and treated with designated doses of adriamycin, emodin or verapamil for 72 h. The cells were double-labeled with Annexin V-APC and DAPI according to the manufacturer’s procedure. The cells were detected in 2 h on BD FACScantoII flow cytometer (BD Biosciences, San Jose, CA). The data were analyzed by FlowJo 7.6.2 software (Tree Star Inc., Ashland, OR). Triplicate experiments were implemented for flow cytometry analysis.

Western blot analysis
P-gp antibody (sc-8313), secondary antibody (sc-2004), β-actin (sc-47778) were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). After treatment with emodin and adriamycin or siRNA transfection, cells were subjected to immuno-blot analysis and proceeded as previously reported [14].

siRNA transfection
K562/ADM cells (5×10^5 cells/ml, 400 μl) were seeded in 24-well plates and transiently transfected with siRNA against P-gp (5′-GCGAAGCAGUGGUUCAGGUTT-3′) for 48 h at the final concentration of 100 nM using Lipofectamine RNAiMAX Reagent according to the manufacturer’s protocol. The negative control (5′-UUCUCGAACGUGUACGUTT-3′) in the transfection was used as a control siRNA. The protein expressions were detected by western blot analysis and cells with P-gp knock down were seeded for the emodin uptake assays.

LC-MS/MS analysis
Liquid chromatography was performed on a Shimadzu LC-2010CHT series chromatographic system (Shimadzu, Nakagyo-ku, Kyoto, Japan) consisting of an on-line solvent degasser, a quaternary gradient pump, an auto-sampler and a column oven. Quantification was achieved with a Thermo-Finnigan TSQ Quantum Ultra AM LC–MS/MS system equipped with an electrospray ionization (ESI) source (Thermo-Finnigan, San Jose, CA, USA). Data acquisition was performed with Xcalibur 1.4 software (Thermo-Finnigan, San Jose, CA, USA). Chromatographic separation was performed on Agilent TC-C18 (5 µm, 150 mm x 4.6 mm) at 35˚C. The mobile phases were water with 0.1% formic acid—acetonitrile (25:75, v/v) for emodin, ammonium formate—formic acid buffer (5 mM ammonium formate and 0.1% formic acid)-methanol (5:95, v/v) for rhodamine 123 at a flow rate of 1.0 ml/min. The auto-sampler was adjusted to 4˚C for optimal stability. Negative ion detection mode was selected for emodin and positive one for rhodamine 123 both with the drying gas temperature of 350˚C, an ion spray voltage of 3.5 kV at a flow-rate of 10 L/min. Quantification was performed by selected reaction monitoring (SRM) mode with precursor-product ion transitions: m/z 268.3 → 224.9 for emodin, m/z 252.9 → 224.9 for chrysophanol (internal standard); m/z 345.2 → 285.2 and 443.3 → 415.2 for rhodamine123 and rhodamine 6G (internal standard) with the collision energies of 44 eV and 35 eV respectively.

Intracellular accumulation of rhodamine 123
The effect of emodin on the intracellular accumulation of rhodamine 123 was determined in Caco-2 cells and P-gp overexpressing K562/ADM cells. Generally, the cells treated with various concentrations of emodin (Caco-2, 10–200 μM; K562/ADM, 0.25–20 μM) and rhodamine 123 (3 μM) were incubated at 37˚C for 120 min. P-gp inhibitor verapamil (200 μM) was also used as a positive control. Then cells were washed in PBS and lysed in 100 μl of 8 M carbamide
solution by sonication. After high speed centrifugation, the cell lysate was spiked with 10 μl internal standard (rhodamine 6G) and 50 μl acetonitrile. After fully vortex-mixed, the mixture was centrifuged at 12,000 rpm for 10 min, and the supernatant was analyzed by LC-MS/MS. Cell protein was quantitated by BCA Protein Assay Kit.

Intracellular uptake of emodin
To further evaluate whether emodin was the substrate of P-gp, the intracellular uptake of emodin was determined in K562 and K562/ADM cells under different condition where P-gp activity was regulated. In detail, the K562 and K562/ADM cells with or without P-gp knockdown were treated with 5 μM emodin alone or combined with classic P-gp inhibitors (verapamil and cyclosporin A) and incubated at 37 or 4˚C for 120 min. The cells were collected and the intracellular amount of emodin was determined by LC-MS/MS as described above. Cell protein was quantitated by BCA Protein Assay Kit.

Interaction between emodin and rhodamine 123 or verapamil
To investigate the interaction between emodin and rhodamine 123, K562/ADM cells were coadmininistrated with different concentrations of emodin (0.25, 0.5, 1, 2.5, 5, 20 μM) with required concentration of rhodamine 123 (1, 3, 10 μM) for 120 min at 37˚C. Similarly, to investigate the interaction between emodin and verapamil, 20 μl rhodamine 123 was added to K562/ADM cells to give a final concentration of 1 μM, and different concentrations of emodin (0.25, 0.5, 1, 2.5, 5, 20 μM) with required concentration of verapamil (0.5, 1, 2 μM) were coadminisntrated for 120 min at 37˚C. The intracellular concentrations of rhodamine 123 were determined by LC-MS/MS method described above. Cell protein was quantitated by BCA Protein Assay Kit.

Calculation of $K_{intrinsic}$ ($K_i$)
The value of $K_i$ is the derived value of the Michaelis parameter standing for the effectiveness of chemosensitisizers on counteracting the effect of P-gp on the accumulation of the substrates of P-gp [6]. The value of $K_i$ was calculated by equation:

$$D_i = D_0 + (D_\infty - D_0) \times C/(K_i \times D_\infty/D_0 + C),$$

where $D_i$ is the intracellular amount of probe (μg/mg protein) when the concentration of inhibitor was C (μg/ml). $D_\infty$ and $D_0$ represent intracellular amount of probe when the concentration of the inhibitors is infinity and infinitesimal. The value of $K_i$ increases when two chemosensitizers coadministered to inhibit P-gp compete with each other while if noncompetition exists, the value of $K_i$ would remain unchanged [15].

Docking studies
The binding modes of emodin with P-gp were further evaluated by molecular docking analysis, which was made with a refined murine P-gp derived from the original crystallographic data (PDB: 3G60), comprising 87% overall sequence identity and nearly 100% identity within the DBP with the exception of mSer725/hAla729 between mouse and human P-gp [16]. The molecular docking analysis was conducted as previously reported with minor modification [17]. In MOE, the R- and M- binding sites of P-gp were defined according to the amino residues mapped by Ferreria et al [18].
Statistical analysis

All experiments were performed in triplicate. Data were presented as mean ± S.D. To test statistically significant differences among multiple treatments for a given parameter, one-way analysis of variance (ANOVA) was performed. A p-value smaller than 0.05 was considered as significant.

Results

Cytotoxicity of emodin

To choose appropriate doses of emodin to add into the cells, the cytotoxic activity of emodin on K562, K562/ADM and Caco-2 cells was evaluated by MTT assay. Emodin inhibited the viability of human leukemia K562 cells and its adriamycin-resistant K562/ADM cells in a dose-dependent and time-dependent manner (Fig 2A and 2B). Emodin of concentrations under 20 μM had a very weak cytotoxicity (cell viability > 80%) to K562 and K562/ADM cells. To minimize the effect of emodin itself on K562 and K562/ADM cells growth, emodin concentrations from 0 to 20 μM were selected for the following experiments. In Caco-2 cells, emodin of 50, 100 and 200 μM and verapamil of 200 μM showed no significant cytotoxicity (Fig 2C) and these concentrations were selected for the following experiments.

Emodin enhanced the sensitivity of K562/ADM cells to adriamycin

The reversing effect of emodin on adriamycin resistance was tested in K562/ADM cells. Verapamil, a well-known P-gp inhibitor, was used as a positive control. As shown in Table 1, emodin enhanced the sensitivity of K562/ADM cells to adriamycin by 1.60, 2.47, 2.96, 4.91, 9.30-fold at the concentrations of 1, 5, 10, 20, 40 μM, respectively, in a dose-dependent manner. The RF value of 10 μM verapamil was 2.66, which was comparable to that of emodin in the same dose, hinting the similar MDR-reversal activity between emodin and verapamil.

To further ascertain the effect of emodin on the adriamycin-induced cytotoxicity in K562/ADM cells, an apoptosis assay was executed in K562/ADM cells treated with adriamycin alone or adriamycin in combination with emodin. Considering the maximal fluorescence spectrum of emodin was between 515 nm and 525 nm, cells were double-stained with annexin V-APC and DAPI in order to avoid fluorescence interference of emodin [19, 20]. As shown in Fig 3, compared with the control group, K562/ADM cells treated with 10, 20 μM emodin or 10 μM adriamycin showed apparent apoptosis with cell apoptosis rates of 7.35%, 10.78% and 11%, respectively. In contrast, treatment of 10 or 20 μM emodin or 10 μM verapamil combined with 10 μM adriamycin brought about a clearly increased cells number in the right areas with the apoptosis percents of 29.3%, 38.3%, 35.6%, respectively (p < 0.01). Therefore, it was demonstrated that emodin could enhance adriamycin-induced apoptosis in K562/ADM cells in a dose-dependent manner with similar effect of verapamil.

Emodin suppressed expression of P-gp protein in K562/ADM cells

Since the reversal of P-gp mediated MDR might be associated with the alteration of protein expression, emodin was examined for the potential to modulate the P-gp protein expression in K562/ADM cells. As illustrated in Fig 4A and 4B, the treatment of 20 or 40 μM emodin alone or combined with 10 μM adriamycin exerted significant downregulation of P-gp protein expression compared with the control group and the group treated with 10 μM adriamycin alone. These results suggested that emodin suppressed P-gp protein expression in human K562/ADM cells, which might contribute to its MDR reversal activity.
Fig 2. Effect of emodin on the viability of K562, K562/ADM cells and Caco-2 cells. The K562 (A), K562/ADM (B) cells were treated with emodin at different doses for 24, 48 or 72 h, Caco-2 (C) cells for 48 h respectively. Data were expressed as means ± standard deviation (S.D.) of three independent experiments.

https://doi.org/10.1371/journal.pone.0187971.g002
Emodin increased intracellular accumulation of rhodamine 123

The decrease of intracellular drug concentrations, a result of the efflux of anticancer drugs in tumor cells, is believed to be a common cause of P-gp-mediated MDR. To investigate whether emodin could inhibit the efflux function of P-gp, the intracellular accumulation of rhodamine 123, a classical substrate of P-gp, was measured in the Caco-2 and K562/ADM cells by LC-MS/MS. As shown in Fig 5, emodin concentration dependently increased the intracellular accumulation of rhodamine 123 in Caco-2 and K562/ADM cells. In Caco-2 cells, emodin exhibited a similar efficiency on the rhodamine 123 accumulation at 20 μM compared with 200 μM verapamil (Fig 5A). These data demonstrated that emodin could inhibit the P-gp efflux function to modulate MDR in K562/ADM cells as well as in Caco-2 cells.

Table 1. Effect of emodin on adriamycin cytotoxicity in K562/ADM cells.

| Treatment            | K562/ADM |
|----------------------|----------|
|                      | IC₅₀ (µM) | RF       |
| Adriamycin           | 10.97    | -        |
| Adriamycin + 1 µM Emodin | 6.34 ± 0.12** | 1.6     |
| Adriamycin + 5 µM Emodin | 4.01 ± 0.15** | 2.47   |
| Adriamycin + 10 µM Emodin | 3.20 ± 0.22** | 2.96   |
| Adriamycin + 20 µM Emodin | 1.53 ± 0.28** | 4.91   |
| Adriamycin + 40 µM Emodin | 0.99 ± 0.17** | 9.30   |
| Adriamycin + 10 µM Verapamil | 3.05 ± 0.25** | 2.66   |

Effect of emodin on the sensitivity of K562/ADM cells toward adriamycin were examined by MTT method as described above. The cells were treated with various concentrations of adriamycin in the presence of emodin for 48 h. The IC₅₀ values for adriamycin were calculated. The results were presented as means ± S. D. from three independent experiments.

*p < 0.05, ** P < 0.01. RF = IC₅₀ of adriamycin / IC₅₀ of adriamycin and emodin in combination.

https://doi.org/10.1371/journal.pone.0187971.t001

Emodin and P-glycoprotein

Fig 3. Effect of emodin on adriamycin-induced apoptosis in K562/ADM cells measured by annexin V-APC/DAPI double-staining assay. The K562/ADM cells were treated with adriamycin (10 µM), emodin (10 and 20 µM) or verapamil (10 µM) alone; or adriamycin (10 µM) combined with emodin (10 and 20 µM) or verapamil (10 µM) for 48 h. Then cells were stained with annexin V-APC and DAPI before being subjected to flow cytometry for analysis. Histogram represented the means ± S.D. values for apoptotic cells obtained from three independent experiments. * P < 0.05; ** P < 0.01.

https://doi.org/10.1371/journal.pone.0187971.g003
Emodin inhibited P-gp function as a substrate

To clarify whether emodin is a substrate of P-gp, the intracellular amount of emodin was determined by LC-MS/MS in sensitive K562 and resistant K562/ADM cells under different conditions where the P-gp function were inhibited. The data showed the amount of emodin in K562 cells was higher than that in the K562/ADM cells at 37˚C (p < 0.01, Fig 6A). In addition, compared with K562/ADM incubated at 37˚C, K562/ADM cells incubated at 4˚C, at which the P-gp efflux activity was inactivated, showed higher intracellular emodin concentrations (p < 0.01). On the contrary, insensitive K562 cells, the intracellular amount of emodin was nearly at a similar level in K562 cells incubated at 37˚C and K562/ADM incubated at 4˚C (Fig 6A). Furthermore, two classic P-gp inhibitors, verapamil and cyclosporine A could effectively increase the accumulation of emodin in K562/ADM cells (Fig 6B). Besides, the RNAi technology was also introduced to down-regulate the P-gp protein level in K562/ADM cells successfully (Fig 6C). Obviously, the concentration of emodin was much higher in the P-gp
knockdown K562/ADM cells compared with that of the controls, while comparable with that in K562 cells (p < 0.01, Fig 6D). All the above results provided reliable evidence that emodin was most likely the substrate of P-gp and it could be effuxed by P-gp.

**Emodin and rhodamine 123 shared the common binding sites in K562/ADM cells**

Previous studies confirmed that the classic substrate of P-gp, rhodamine 123, acts with P-gp on the binding site called R [21 22]. Since the present study showed that emodin was a substrate of P-gp, the competition style between emodin and rhodamine 123 was investigated to see whether the two substrates shared the same binding sites when pumped out by P-gp. The
three curves in Fig 7A showed the increase of rhodamine 123 accumulation brought about by increasing variable substrate emodin at the range of 0 to 20 μM, while the fixed substrate rhodamine 123 was set at 1, 3 and 10 μM. From each curve, the values of $K_i$ for emodin were computed and plotted against the rhodamine 123 concentrations. The $K_i$ clearly increased consistently with the increasing rhodamine 123 concentrations (Fig 7B), indicating competition interactions between emodin and rhodamine 123. Thus, based on the data obtained, it could be concluded that emodin and rhodamine 123 may share the same R binding site as P-gp substrates.

Emodin displayed noncompetition with verapamil

Apart from rhodamine 123 as a substrate probe, the classic inhibitor verapamil which binds to P-gp at the binding sites called the M site was also used as a fixed modulator to verify the binding sites of emodin on P-gp [18, 23]. The calculated $K_i$ values were obtained for emodin and plotted against the verapamil concentrations. As shown in Fig 7D, the $K_i$ of emodin was almost
unchanged with increasing verapamil concentrations, confirming that emodin and verapamil were non-competitors or else very weakly competitive. Consequently, it is reasonable to conclude that verapamil increased the accumulation of emodin in a non-competition style at the M site (Fig 6B).

**Molecular docking analysis**

To further verify the detailed modes of emodin interacting with P-gp on R- and M- binding sites, molecular docking was performed among emodin and the X-ray crystal structure of P-gp. According to the molecular docking results, emodin bound to the R binding site with the binding free energy of -28.612 kcal/mol (Table 2). As shown in Table 2, Fig 8A and 8A’, at R binding site, emodin formed seven H-bonds with residues Ala 830, Ala714, Gln 769, Asn 717, Gln 986, and provided two strong \( \pi - \pi \) interactions with Phe 990 and Phe 833. In contrast, it bound to the M site with a less negative binding free energy of -21.437 kcal/mol (the less negative binding free energy of emodin with P-gp binding sites means the less easier interaction with P-gp) than that of R site and formed only one \( \pi - \pi \) interaction with Phe 728 as well as two H-bonds with Ser 975 and Tyr 303 at the M site (Table 2, Fig 8B and 8B’). Combined, emodin could bind to the R binding site of P-gp with a much higher affinity than to the M site.

Fig 7. Effect of emodin combined with various amount of rhodamine 123 or verapamil on inhibition of P-gp. K562/ADM cells were incubated with emodin (0.25–20 \( \mu \)M), together with 1, 3, 10 \( \mu \)M of rhodamine 123, respectively (A); The \( K_i \) of emodin was calculated and plotted against the concentrations of rhodamine 123 (B). K562/ADM cells were incubated with emodin (0.25–20 \( \mu \)M) with 0.5, 1, 2 \( \mu \)M of verapamil and 1 \( \mu \)M of rhodamine 123 (C). The calculated values of \( K_i \) for emodin were plotted against the concentrations of verapamil (D). Data were represented as the mean ± S.D of three independent experiments.

https://doi.org/10.1371/journal.pone.0187971.g007
Multidrug resistance (MDR) is an obstacle to successful cancer chemotherapy [24], one of the main mechanisms being the overexpression of P-gp. Similarly, P-gp mediated MDR in CML is also a key factor that leads to the failure of imatinib-based chemotherapy [25, 26]. K562/ADM, a P-gp-overexpressed adriamycin resistant CML cell line, shows resistance not only to adriamycin itself, but also to a broad range of anticancer reagents, including vincristine, etoposide and the one line CML chemotherapeutic drug imatinib [27, 28]. Consequently, the K562/ADM cell line was selected to evaluate the reversal effects of emodin on MDR in CML and to investigate whether emodin is the substrate of P-gp as well as its binding sites to P-gp.

In our study, emodin significantly reversed the adriamycin resistance in K562/ADM cells, which was also confirmed by the apoptosis assay. The results of western blot analysis revealed that emodin alone or combined with adriamycin concentration dependently decreased the P-gp protein level. Meanwhile, emodin increased the intracellular amount of rhodamine 123 in

![Fig 8. Docking views of emodin with P-gp.](https://doi.org/10.1371/journal.pone.0187971.g008)
both Caco-2 and K562/ADM cells. In other words, emodin is an effective inhibitor of P-gp by indirect mechanisms related to the decrease of P-gp protein expression or directly binding to P-gp and then weakening the P-gp function, coincident with previous reports [9, 10, 29]. In addition, the LC-MS/MS method was established for the assay of rhodamine 123 and emodin in K562/ADM and Caco-2 cells owing to the strong fluorescence interference between emodin and rhodamine 123 as a result of the maximum emission wavelength of the two compounds both being around 525 nm [19, 30].

As for whether emodin was the substrate of P-gp, it was previously proposed that emodin was the potential substrate of P-gp [11]. Differently, Zhang et al reported that emodin was not the substrate of P-gp based on a one way intestinal perfusion rat model [12]. Herein, to clarify the discrepancy, many methods were applied to inhibit the function of P-gp. RNAi, one of the most powerful tool to suppress the protein expression, was introduced to down regulate the P-gp protein level in K562/ADM cells. Besides, at 4˚C, the P-gp efflux function will be weaken [31, 32], thus the K562/ADM cells were incubated both at 37 and 4˚C. Moreover, the classical P-gp inhibitors verapamil and cyclosporine A were also used. As shown, when the P-gp protein level was decreased or the P-gp efflux function was inhibited, the intracellular amount of emodin remarkably increased, which proved that P-gp mediated the efflux of emodin in K562/ADM cells. In conclusion, consistent with Li et al [11], it was more comprehensively and reasonably recognized that emodin was a substrate for P-gp.

In successive years, many efforts were paid to elucidate the presence of multiple drug binding sites on P-gp. Safa et al have reported by kinetic analysis that vinblastine and cyclosporin A competitively interact competitively with a common binding site on P-gp whereas they noncompetitively interact with the azidopine-binding site, which indicate there are more than one binding site of P-gp [33,34]. Later, a more complete view believed that three drug binding sites existed on P-gp [21]. More recently, after the the publication in 2009 of the murine crystallographic structure that clarified P-gp’s structural properties, three putative drug-binding sites were hereby characterized by means of molecular docking, two of which are named as R (Rhodamine) site and M (modulatory) site [18,23,35]. Previous studies indicated that rhodamine 123 and photoaffinity analogs of verapamil could both bind specifically to p-gp [36, 37]. Competition studies confirmed that rhodamine 123 bound to the R site preferentially [21], while molecular docking studies show that verapamil binds to the M site as a modulator [18].

The clarification of explicit binding sites of emodin on P-gp will provide vital information for chemical modification to develop emodin into an effective P-gp inhibitor, thereby, the investigation of the emodin binding sites is of important priority. Hence, in the present study, competition studies were performed between emodin and rhodamine 123 or verapamil for the first time. The $K_i$ values of emodin were calculated according to the formula created by Stein’s group based on the classical Michaelis-Menten scheme, which successfully described the competitive, noncompetitive, and cooperative interactions between several P-gp modulators [15]. A competitor binds to the same site when it competes with other substrates and the value of $K_i$ increased linearly with the concentration of other substrates, while if noncompetition exists, the $K_i$ value will be unchanged [6, 15].

Meaningfully, the $K_i$ of emodin increased linearly with the concentrations of rhodamine 123 while remained nearly unchanged with increasing verapamil concentrations, which indicated emodin competitively bound to P-gp with rhodamine 123 at the R site, defined as a transport site, whereas no or else very weak competition existed between verapamil and emodin. These results were consistent with previous studies that most modulators displayed their MDR reversal activities by competitively binding to the transport site [38]. Nevertheless, it was still uncertain whether emodin could bind to the M site.

Molecular docking analysis helped to provide much more information on the interaction modes of emodin with P-gp drug binding sites. According to amino residues mapped by
Ferreia et al [18], the R- and M- sites of P-gp were defined as the docking cavity of emodin for the first time. Then, the binding free energies and the interactions of emodin at R- and M-sites were obtained to evaluate the binding affinity of emodin. Generally, the more negative binding free energy means the easier interaction with each other. The docking studies showed that emodin bound to the R site with a more negative binding free energy than to the M site and formed more Pi interactions and H bonds at R site, which were in reasonable agreement with the observed results of competition experiments that emodin competed with rhodamine 123 (R site) rather than verapamil (M site) at P-gp. Partially coincident with our results, it was reported by Li et al that emodin had four potential Pi interactions with Phe974 and Phe728 in the internal cavity of P-gp [11]. As to the differences between the docking studies, it had to be noted that our docking cavity was refined in the R- and M- sites at P-gp respectively while Li et al performed the docking study in the whole internal cavity of P-gp. In comparison, our docking studies provided more accurate binding modes of emodin at the R- and M- sites. Additionally, due to the lack of a high resolution crystal structure of human P-gp, all molecular docking analysis was based on the crystal structure of mouse P-gp [35] or different homology model structures of human P-glycoprotein [39–41], therefore it could be understood that in some cases the docking data showed a great amount of controversy. All in all, the binding sites of emodin on P-gp needs further confirmation in future studies.

Conclusion

In summary, the present study verified that emodin reversed P-gp mediated MDR in K562/ADM cells through the inhibition of P-gp protein expression and its drug efflux function as a substrate. Our data firstly provided direct evidence that there is competitive interaction among emodin and rhodamine 123 at the R site of P-gp, whereas emodin noncompetitively bound to the M site with verapamil. Taken together, we suggest that emodin might be used to modulate P-gp function and expression. In future, more detailed pharmacokinetic and pharmacodynamics studies are needed to reveal the underlying molecular mechanisms of emodin in the reversal of P-gp mediated MDR.

Acknowledgments

All authors sincerely extend their thanks to the Department of Pharmaceutical Analysis, China Pharmaceutical University for its support in laboratory logistics required for this study.

Author Contributions

Conceptualization: Jia Yan, Bin Di, Fang Yan.
Formal analysis: Hongping Min, Weilin Zhang.
Funding acquisition: Fang Yan.
Investigation: Hongping Min, Jia Yan.
Methodology: Jiachang Li.
Project administration: Hongping Min.
Resources: Miaomiao Niu, Xiying Tan, Fang Yan.
Software: Miaomiao Niu.
Supervision: Weilin Zhang, Bin Di, Fang Yan.
Visualization: Hongping Min.
References

1. Takahashi Naoto M I, Saitoh Kohki, and Miura Akira B.. Lineage Involvement of Stem Cells Bearing the Philadelphia Chromosome in Chronic Myeloid Leukemia in the Chronic Phase as Shown by a Combination of Fluorescence-Activated Cell Sorting and Fluorescence In Situ Hybridization. Blood. 1998; 92 (12): 4758–63. PMID: 9845542

2. Kurzrock R, Gutteman JU, Talpaz M. The molecular genetics of Philadelphia chromosome-positive leukemias. N Engl J Med. 1988; 319(15):990–8. https://doi.org/10.1056/NEJM198810133191506 PMID: 3047582

3. Corrêa S, Binato R, Rocher BD, Castelobranco MT, Pizzatti L, Abdelhay E. Wnt/β-catenin pathway regulates ABCB1 transcription in chronic myeloid leukemia. BMC Cancer. 2012; 12(1):303.

4. Souza PS, Vasconcelos FC, DSR Fr, Nestal DMG, Maia RC. P-glycoprotein and survivin simultaneously regulate vincristine-induced apoptosis in chronic myeloid leukemia cells. Int J Oncol. 2011; 39 (4):925–33. https://doi.org/10.3892/ijo.2011.1103 PMID: 21720708

5. Kosztyu P, Dolezel P, Mlejnek P. Can P-glycoprotein mediate resistance to nilotinib in human leukemia cells? Pharmaco1 Res. 2012; 67(1):79–83. https://doi.org/10.1016/j.phrs.2012.10.012 PMID: 23103446

6. Feng Y, Hu Y, Cen J, Darshika KN, Fang W, Li Y, et al. HZ08 inhibits the multi-drug resistance on multiple sites as the substrate of p-glycoprotein. Eur J Pharmacol. 2013; 712(1):53–9.

7. Huang Q, Lu G, Shen HM, Chung MC, Ong CN. Anti-cancer properties of anthraquinones from rhubarb. Med Res Rev. 2007; 27(5):609–30. https://doi.org/10.1002/med.20094 PMID: 17022020

8. Chen YY, Li J, Hu JD, Zheng J, Zheng ZH, Zhu LF, et al. [Reversing effects of emodin on multidrug resistance in resistant HL-60/ADR cells]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2013; 21(6):1413–22. PMID: 24370022

9. Ayesh S, Shao YM, Stein WD. Co-operative, competitive and non-competitive interactions between modulators of P-glycoprotein. Biochim Biophys Acta. 1996; 1316(1):8–18. PMID: 8634345

10. Dolghih E, Bryant C, Renslo AR, Jacobson MP. Predicting Binding to P-Glycoprotein by Flexible Receptor Docking. PLoS Comput Biol. 2011; 7(8):e1002083. https://doi.org/10.1371/journal.pcbi.1002083 PMID: 21731480

11. Niu M, Gu Y. An in silico protocol for identifying poly(ADP-ribose)polymerase-1 (PARP-1) inhibitors from chemical databases. New Journal of Chemistry. 2015; 39(2):1060–6.

12. Ferreira RJ, Ferreira MJ, dos Santos DJ. Molecular docking characterizes substrate-binding sites and efflux modulation mechanisms within P-glycoprotein. J Chem Inf Model. 2013; 53(7):1747–60. https://doi.org/10.1021/ci400195v PMID: 23802684

13. Wang XF, Jun-Bo GE, Wang KQ, Qian JY. Effects of emodin on fluorescence analysis. Fudan Univ J Med Sci. 2006; 33(2):262–5.
20. Mai LP, Zhong SL, Yang M, Xi-Yong YU, Shan ZX, Lin QX. Compare two different staining methods used in flow cytometric analysis of cell cycle. J Trop Med. 2011; 11(12):1363–6.

21. Shapiro AB, Ling V. Positively Cooperative Sites for Drug Transport by P-Glycoprotein with Distinct Drug Specificities. Eur J Biochem. 1997; 250(1):130–7. PMID: 9432000

22. Lugo MR, Sharom FJ. Interaction of LDS-751 with P-glycoprotein and mapping of the location of the R drug binding site. Biochemistry. 2005; 44(2):643–55. https://doi.org/10.1021/bi0485326 PMID: 15641790

23. Zeino M, Saeed ME, Kadioglu O, Efferth T. The ability of molecular docking to unravel the controversy and challenges related to P-glycoprotein—a well-known, yet poorly understood drug transporter. Invest New Drugs. 2014; 32(4):618–25. https://doi.org/10.1007/s10637-014-0098-1 PMID: 24748336

24. Persidis A. Cancer multidrug resistance. Nat Biotechnol. 1999; 17(1):94–5. https://doi.org/10.1038/5289 PMID: 9920278

25. Mahon Francois-Xavier B, rie Lagarde Vale’, Chollet Claudine, Franc Josy Reiffers, Goldman John M., and Melo Junia V.. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood. 2003; 101(6):2368–73. https://doi.org/10.1182/blood.V101.6.2368 PMID: 12609962

26. Illmer T, Schaich M, Platzbecker U, Freiberg-Rich ter J, Oelschlag el U, von Bonin M, et al. P-glycop rotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia. 2004; 18(3):401–8. https://doi.org/10.1038/sj.leu.2403257 PMID: 14724652

27. Wu L, Li S, Chen XL, Zeng XF, Wu JZ, Zhu CR, et al. Identification of galectin-1 as a novel mediator for chemoresistance in chronic myeloid leukemia cells. Oncotarget. 2016; 7(18):26709–23. https://doi.org/10.18632/oncotarget.8489 PMID: 27050374

28. Wang DH, Wei HL, Zhao HS, Hao CY, Min ZH, Liu JM. Arsenic trioxide overcomes apoptosis inhibition in K562/ADM cells by regulating vital components in apoptotic pathway. Pharmacol Res. 2005; 52(5):376–85. https://doi.org/10.1016/j.phrs.2005.05.010 PMID: 15979894

29. Liu DL, Bu H, Li H, Chen H, Guo HC, Wang ZH, et al. Emodin reverses gemcitabine resistance in pancreatic cancer cells via the mitochondrial apoptosis pathway in vitro. Int J Oncol. 2012; 40(4):1049–57. https://doi.org/10.3892/ijo.2011.1285 PMID: 22159556

30. Lu X, Lloyd DK, Klohr SE. Feasibility of Using Fluorescence Spectrophotometry to Develop a Sensitive Dye Immersion Method for Container Closure Integrity Testing of Prefilled Syringes. Pda Journal of Pharmaceutical Science & Technology. 2016; 70(1):39–50.

31. Müller F, König J, Hoier E, Mandery K, Fromm MF. Role of organic cation transporter OCT2 and multi-drug and toxin extrusion proteins MATE1 and MATE2-K for transport and drug interactions of the antiviral lamivudine. Biochemical Pharmacology. 2013; 86(6):808–15. https://doi.org/10.1016/j.bcp.2013.07.008 PMID: 23876341

32. Teng Z, Zhou S, Ran Y, Liu X, Yang R, Yang X, et al. Cellular Absorption of Anthraquinones Emodin and Chrysophanol in Human Intestinal Caco-2 Cells. Bioscience Biotechnology & Biochemistry. 2014; 71(7):1636–43.

33. Tamai I, Safa AR. Azidopine noncompetitively interacts with vinblastine and cyclosporin A binding to P-glycoprotein in multidrug resistant cells. Journal of Biological Chemistry. 1991; 266(25):16796–800. PMID: 1679434

34. Safa AR. Identification and characterization of the binding sites of P-glycoprotein for multidrug resistance-related drugs and modulators. Curr Med Chem Anticancer Agents. 2004; 4(1):1–17. PMID: 14754408

35. Aller SG, Yu J, Ward A, Weng Y, Chittaboina S, Zhuo R, et al. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science. 2009; 323(5922):1718–22. https://doi.org/10.1126/science.1168750 PMID: 19325113

36. Nare B, Liu Z, Pritchard RK, Georges E. Benzimidazoles, potent anti-mitotic drugs: substrates for the P-glycoprotein transporter in multidrug-resistant cells. Biochemical Pharmacology. 1994; 48(12):2215–22. PMID: 7811303

37. Safa AR. Photoaffinity labeling of the multidrug-resistance-related P-glycoprotein with photoactive analogs of verapamil. Proceedings of the National Academy of Sciences of the United States of America. 1988; 85(19):7187–91. PMID: 2902625

38. Wang RB, Kuo CL, Lien LL, Lien EJ. Structure-activity relationship: analyses of p-glycoprotein substrates and inhibitors. J Clin Pharm Ther. 2003; 28(3):203–28. PMID: 12795780

39. Domicicva L, Biggin PC. Homology modelling of human P-Glycoprotein. Biochemical Society Transactions. 2015; 43(5):952–8. https://doi.org/10.1042/BST20150125 PMID: 26517909
40. Gadhe CG, Kothandan G, Cho SJ. In silico study of desmosdumotin as an anticancer agent: homology modeling, docking and molecular dynamics simulation approach. Anti-cancer agents in medicinal chemistry. 2013; 13(10):1636–44. PMID: 23796247

41. Daddam JR, Dowlatabad MR, Panthangi S, Jasti P. Molecular docking and P-glycoprotein inhibitory activity of flavonoids. Interdisciplinary Sciences: Computational Life Sciences. 2014; 6(3):167–75.